Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Latest Corporate Presentation (Nov 27,2024).

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Dec 03, 2024 8:40pm

205 Views

Post# 36344232

RE:Latest Corporate Presentation (Nov 27,2024).

Thanks for the link to the new corporate presenttion wildbird1. I am quite puzzled by a line on pg. 3

Theralase Strategic Objectives

2Q2025 to 4Q2025

• Enroll 25 remaining patients in Phase II bladder cancer registration clinical study (“Study II”) (75 patients enrolled and treated to date)

Does this mean Theralase doesn't plan on treating any patients in the next 4 months?

Maybe they will clarify tomorrow morning...

wildbird1 wrote:
Theralase Corporate Presentation - 11 27 2024 (002) - Adobe cloud storage

Page 17....
Is it just me or the CR% at 450 days is still at 43.6%CR.

As I said before Ruvidar is 130% more potent than Merck best treatment Keytruda(18.9%CR at 450 days), and Keytruda doesn't even treat immuno-deficients patients.

Watch out Merck, TLT-Ruvidar is coming!
A word of advice for Merck, talk to Dr.Lbiati while you still can.

I love my TLT shares.